NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
1. "Bonzyme" Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder.
2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability.
3. Exclusive “Bonpure” seven-step purification technology, high purity (up to 99%) and stability of production of NMNH powder
4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder
5. Provide one-stop product solution customization service
The main methods of NMNH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme becomes the mainstream method owing to the advantages of pollution free, high level of purity and
When applied to cultured cells, the NMNH is shown to be more efficient than NMN as it was able to “significantly increase NAD+ at a ten times lower concentration (5 µM) than that needed for NMN”. Moreover, NMNH shows to be more effective , as at 500 µM concentration, it achieved “an almost 10-fold increase in the NAD+ concentration, while NMN was only able to double NAD+ content in these cells, even at 1 mM concentration.”.
Interestingly, NMNH also appears to act quicker and has a longer-lasting effect compared to NMN. According to the authors, NMNH induces a “significant increase in NAD+ levels within 15 minutes”, and “NAD+ steadily increased for up to 6 hours and remained stable for 24 hours, while NMN reached its plateau after only 1 hour, most likely because the NMN recycling pathways to NAD+ had already become saturated.”.
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
Nicotinamide adenine dinucleotide (NAD+ ) homeostasis is constantly compromised due to degradation by NAD+ -dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors.
First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Introduction On March 16, 2024, the world famous Clinical Laboratory Practice Expo (CACLP) and China IVD Supply Chain Expo (CISCE) were inaugurated at Chongqing International Expo Center. As a leading supplier of raw materials for coenzyme and natural products, BONTAC was invited to participate this industry feast, providing global partners with one-stop service for customized solution in the field of green synthetic biology. About 2024 CACLP&CISCE This exhibition is themed by “Shaping a Smart Future Through Collaboration”, covering 130,000 square meters, with over 1400 enterprises and more than 100 high-end academic conferences. The representatives from more than 20 countries and regions at home and abroad, encompassing the upstream, midstream and downstream of in vitro diagnostics (IVD) industry chain, are attracted to participate in this globalized and comprehensive industry top event, and display their latest instruments and devices, innovative detection technology and overall solutions in IVD industry. High-end active raw materials of BONTAC in 2024 CACLP&CISCE BONTAC keeps up with the development direction and cutting-edge trends of the industry, and brings many patent-grade core active raw materials to the exhibition. Noteworthily, BONTAC has 174 international invention patents up until now. Its main products involve coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates. During the exhibition, many high-quality enzyme products from BONTAC, including NMN, NAD, NADH, NADP and NADPH, fuel the interest of visitors from all over the world for exchange, consultation and negotiation. BONTAC sales team serves in a professional manner, winning wide recognition from customers and exhibition guests. They provided customers with comprehensive and detailed product information, as well as in-depth technical support and market analysis to ensure that every customer can find the most suitable product solution for their needs. The significance of laboratory medicine and in vitro diagnostics Laboratory medicine and in vitro diagnostics function as the important pillars in the field of medicine, playing an important role in the prevention, diagnosis and treatment of diseases. Accurate, rapid and reliable testing results can help doctors to develop scientific treatment protocol, which are crucial for the operation of the entire medical system and health management. Conclusion BONTAC looks forward to cooperating with more like-minded enterprises via interaction in 2024 CACLP&CISCE to jointly promote the development and prosperity of synthetic biology industry. Looking ahead, BONTAC will continue to focus on the research and innovation in the field of synthetic biology, and provide more high-quality and efficient products and services to global partners.
Introduction Ginsenoside Rh2 nanoliposome formulation has been proved to effectively target and deliver drugs to the tumor site, with less side effects and higher treatment efficiency, holding great promise in the treatment of tumors including breast cancer. Dilemma of traditional tumor therapies The traditional tumor therapies (eg. surgery, radiation, and chemotherapy) carry the high risks of damaging normal tissues and incompletely eradicating the cancer. Strikingly, nanotechnology opens up novel opportunities for tumor treatment, which can enhance earlier diagnosis through in vitro assays, promote imaging capabilities for diagnosis and treatment monitoring, and improve therapeutic outcomes by refining targeting precision, augmenting localized drug efficacy as well as minimizing systemic toxicity. Limitations of conventional liposome formulations The conventional liposome formations encounter a lot of bottlenecks in improving the progress of tumor microenvironment, a vital complex ecosystem for cancer development and metastasis. In addition, these formulations face the trouble (eg. issues related to religion tradition and vegetarianism) brought by cholesterol, an ingredient of traditional liposomes. Moreover, there are disadvantages of complicated fabrication process, low targeting efficiency of ligand-modified liposomes as well as extended circulation time of liposomes caused by the utilization of polyethylene glycol. Merits of PTX-Rh2-Lipo PTX-Rh2-lipo, a potential nanomedicine, has an overtly smaller particle size and higher zeta potential when compared with PTX-C-Lipo. Both types of liposomes show analogous encapsulation and stabilization abilities, as manifested by similar polydispersity index, encapsulation efficiency, and loading efficiency. Different from conventional wooden liposomes, PTX-Rh2-Lipo has the merits of enhanced uptake in tumor-associated fibroblasts L929 and 4T1 breast cancer cells, high targeting and penetration capacity, cytotoxicity against L929 fibroblasts, normalization of the vessel network, and depletion of stromal collagen. Conclusion Rh2-lipo cannot kill 4T1 breast cancer cells alone, despite of its stronger penetration ability in the tumors. Yet, it can act as a delivery vehicle for paclitaxel (PTX) to enhance its antitumor properties. Specifically, in this novel Rh2-Lipo-based nano-carrier PTX-Rh2-lipo, ginsenoside Rh2 can not only serve as a multifunctional membrane material to stabilize the structure and prolong the blood circulation of liposomes, but also works as an active ingredient to synergically enhance the efficacy of anti-cancer drugs by remodeling tumor-associated microenvironment and stimulating the immune system. Reference [1] Alrushaid N, Khan FA, Al-Suhaimi EA, et al. Nanotechnology in Cancer Diagnosis and Treatment. Pharmaceutics. 2023; 15(3):1025. doi: 10.3390/pharmaceutics15031025 [2] Hong C, Liang J, Xia J, et al. One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy. Nanomicro Lett. 2020;12(1):129. doi:10.1007/s40820-020-00472-8 [3] Hong C, Wang A, Xia J, et al. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy. Int J Nanomedicine. 2024;19:2879-2888. doi:10.2147/IJN.S437733 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Introduction Hepatocellular carcinoma (HCC) is hypervascular solid tumor with rapid deterioration, poor overall prognosis and a high recurrence rate, accounting for 90% of primary liver cancers, which has been perceived as the third most common cause of cancer-related mortality across the world. Notably, 20(S)-ginsenoside Rh2, an essential bioactive ingredient derived from ginseng, shows significant anti-tumor effects in various types of cancers, including HCC. About HCC There are diversified risk factors for HCC, mainly encompassing genetics, epigenetic alterations, chronic hepatitis B and C virus infections, aflatoxin exposure, smoking, obesity, and diabetes mellitus. The major therapies for HCC involve surgical excision, ablation, transcatheter arterial chemoembolization, radiotherapy, transplantation, etc. However, the overall prognosis of patients remains unsatisfactory due to the high recurrence and metastasis of HCC. Transplantation is the most effective one, yet rare matched donor livers and high surgical cost limit its application. In addition, more than 70% of advanced patients are not suitable for transplantation, either due to tumor burden or poor liver function. The anti-angiogenetic role of ginsenoside Rh2 in HCC Given that HCC has prominent characteristics of abnormal vascularization and angiogenesis and HCC endothelial cells are prone to forming new blood vessels in situ and supporting metastasis, targeting endothelial cell function to repress angiogenesis may be a highly promising treatment avenue for HCC. Remarkably, 20(S)-ginsenoside Rh2 has effective anti-angiogenic activity, which can exert anti-proliferative, pro-apoptotic, and cell cycle-modulating properties in HCC cell line HepG2 by reducing VEGF and MMP-2 expressions. Repressive role of 20(S)-ginsenoside Rh2 in HCC via GPC3/Wnt/β-catenin signaling 20(S)-ginsenoside Rh2 inhibits HCC growth via suppressing Wnt/β-catenin signaling pathway-related markers (β-catenin, c-myc, and cyclin D1) and GPC3, a cell-surface glycoprotein specifically overexpressed in HCC patients. Specifically, GPC3 silencing promotes 20(S)-ginsenoside Rh2-induced anti-proliferative and pro-apoptotic effects in HepG2 cells, concomitant with the downregulation of β-catenin, c-myc and cyclin D1. Conclusion 20(S)-ginsenoside Rh2 not only inhibits angiogenesis by downregulating VEGF and MMP-2 expressions, but also targets GPC3 by downregulating the Wnt/β- catenin signaling pathway in HCC cells, opening up new opportunities for HCC treatment. Reference Kang I, Koo M, Jun JH, Lee J. Effect of nicotinamide mononucleotide on osteogenesis in MC3T3-E1 cells against inflammation-induced by lipopolysaccharide. Clin Exp Reprod Med. Published online April 11, 2024. doi:10.5653/cerm.2023.06744 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.